| Patent application number | Description | Published |
|---|
| 20080213267 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 09-04-2008 |
| 20080305104 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 12-11-2008 |
| 20090068182 | Cytotoxicity mediation of cells evidencing surface expression of CD9 - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 03-12-2009 |
| 20090142263 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 06-04-2009 |
| 20090191118 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 07-30-2009 |
| Patent application number | Description | Published |
|---|
| 20090084897 | SEATING SYSTEM AND A PASSENGER ACCOMMODATION UNIT FOR A VEHICLE - A passenger seat assembly for a vehicle, particularly an aircraft, which is adpated to provide self-contained, individual seating and sleeping accommodation for a passenger, said seating assembly includes a supporting structure ( | 04-02-2009 |
| 20100019086 | SEATING SYSTEM AND PASSENGER ACCOMMODATION UNIT FOR A VEHICLE - A seat module for a passenger vehicle is disclosed. The seat module includes a seat portion, a foot-rest portion, and a unitary supporting structure for supporting the seat portion and the foot-rest portion off the floor of the vehicle. Two spaced fixings are provided for fixing the supporting structure to one of a pair of seat tracks in a floor of the vehicle at two spaced points. A third fixing is provided for fixing the supporting structure to the other track, to thereby provide a 3-point fixing between the seat module and the seat tracks for attaching the supporting structure to the pair of seat tracks. A plurality of the seat modules can be attached to a pair of seat tracks, one adjacent another, thereby to form a plurality of seat units. Each seat unit includes the seat portion of one module and the foot-rest portion of another, adjacent module. | 01-28-2010 |
| 20100025530 | SEATING SYSTEM AND A PASSENGER ACCOMMODATION UNIT FOR A VEHICLE - A recliner seat assembly for a passenger vehicle is disclosed. The recliner seat assembly includes a fixed supporting portion for supporting the assembly off a floor of the vehicle, a reclinable seat portion comprising a seat-pan and a back-rest, and a seat connecting device adapted for connecting the seat portion to the supporting portion. The connecting device includes a seat reclining mechanism adapted for allowing and controlling translational movement of the seat portion relative to the supporting portion between a first upright position and a second fully reclined position. The connecting device further includes a selectively operable, bi-directional motor adapted for driving the seat portion between the first and second positions. The seat reclining mechanism includes a guiding device for reclining the back-rest progressively rearwardly relative to the supporting portion as the seat portion is moved from the first upright position to the second fully reclined position. | 02-04-2010 |
